Simufilam: Clinical Trials

3 trials of Simufilam, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 2, Completed 1

Follow Simufilam: new trials by email Literature Review of Simufilam trials Research Report on Simufilam

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Simufilam - Alzheimer Disease
Phase 3TerminatedCassava Sciences, Inc.10812022-11-072025-05-23
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Simufilam, Placebo - Alzheimer Disease
Phase 3TerminatedCassava Sciences, Inc.11252021-11-182025-09-22
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
Simufilam, Placebo - Alzheimer Disease
Phase 3CompletedCassava Sciences, Inc.8042021-11-032025-05-25

Conditions studied

Alzheimer Disease (3)

Sponsors

Cassava Sciences, Inc. (3)

Countries

Canada (3)  ·  United States (3)  ·  Australia (2)  ·  Puerto Rico (2)  ·  South Korea (2)

Top investigators

James Kupiec, MD (3)

Results publications

PMID 41500915